Sun Pharmaceutical Industries Ltd.

BSE: SUNPHARMA524715ISIN INE044A01036

Healthcare
Pharmaceuticals
BSE SENSEX

BSE listing

Share price

₹1,835.50-30.50 (-1.63%)

as of 18 Sep 2026

52W high: ₹2,047.55
52W low: ₹1,547.25
Off 52W high: -10.36%
1M return: -3.29%
3M return: -0.09%
6M return: +3.27%
1Y return: +11.32%
20D avg volume: 1,32,405
50 DMA: ₹1,922.89
200 DMA: ₹1,806.48

Key ratios Consolidated

Market cap: ₹4,40,388 Cr
Current price: ₹1,835.50
52W high / low: ₹2,047.55 / ₹1,547.25
Face value: ₹1.00
P/E: 36.35
P/B: —
EPS (TTM): ₹50.50
Book value / share: —
ROE: —
ROCE: 17.90%
Operating margin: —
Net margin: —
Debt / equity: 0.05
Net debt: ₹-5,689 Cr
Interest cover: 45.61
Dividend yield: 0.87%
Dividend / share (TTM): ₹16.00
Payout: 31.68%
Cash conversion cycle: 122.8 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	15,300	14,612	15,521	14,478	13,851	12,959	13,675	13,291	12,653	11,983	12,381	12,192
	723.62	458.50	578.84	469.92	464.46	612.87	465.62	354.00	532.55	605.94	250.20	293.61
	11,721	11,519	11,383	10,781	10,325	9,956	10,349	10,048	9,762	9,672	9,561	9,695
	2,026	2,182	1,813	1,622	1,772	1,845	1,408	1,639	1,557	1,677	1,710	1,665
	1,020	753.34	922.42	1,088	1,048	1,037	1,239	875.10	997.43	982.88	796.49	1,007
	3,227	2,960	2,892	2,765	2,802	2,489	2,552	2,478	2,455	2,299	2,363	2,364
	99.67	85.89	78.36	99.86	74.80	49.14	51.51	69.17	61.54	73.57	34.73	49.29
	738.72	775.47	732.33	729.50	700.55	663.79	630.56	625.91	655.13	650.36	622.14	632.82
	4,692	4,896	4,735	4,204	3,933	4,117	4,190	4,309	3,865	4,212	3,928	3,827
	4,303	3,551	4,717	4,168	3,991	3,616	3,793	3,598	3,424	2,917	3,070	2,791
	-204.09	0.00	-489.48	0.00	-818.00	-361.68	-316.17	0.00	0.00	-101.64	-69.81	0.00
	4,099	3,551	4,227	4,168	3,173	3,254	3,476	3,598	3,424	2,816	3,000	2,791
	1,188	827.62	826.07	1,031	870.15	1,094	558.86	567.21	552.25	148.93	432.32	390.10
	2,901	2,710	3,381	3,125	2,293	2,154	2,913	3,037	2,861	2,659	2,561	2,385
	12.10	11.30	14.00	13.00	9.50	9.00	12.10	12.70	11.80	11.10	10.50	9.90
Key metrics
	4,937	4,413	5,038	4,997	3,948	3,967	4,158	4,293	4,140	3,539	3,657	3,473
	32.30%	30.20%	32.50%	34.50%	28.50%	30.60%	30.40%	32.30%	32.70%	29.50%	29.50%	28.50%
	19.00%	18.50%	21.80%	21.60%	16.60%	16.60%	21.30%	22.90%	22.60%	22.20%	20.70%	19.60%
	—	4.20%	—	5.30%	—	4.50%	—	—	—	—	—	—
	10.50%	12.80%	13.50%	8.90%	9.50%	8.10%	10.50%	9.00%	—	—	—	—
	26.50%	25.80%	16.10%	2.90%	-19.80%	-19.00%	13.80%	27.30%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	59,911	58,462	52,578	48,497	43,886	38,654	33,498	32,838	29,066	26,489
	2,231	1,972	1,965	1,354	634.52	921.51	835.52	635.98	1,025	838.76
	45,403	44,007	40,114	38,269	34,940	30,528	27,228	28,203	25,067	22,899
	7,644	7,389	6,449	6,904	7,778	7,049	6,153	5,515	5,783	4,463
	3,783	3,812	4,148	3,466	3,572	3,410	3,175	3,414	2,519	2,731
	11,844	11,419	9,973	9,429	8,296	7,301	6,862	6,362	5,967	5,367
	363.78	338.91	231.36	238.47	172.00	127.35	141.43	302.73	555.25	517.57
	2,976	2,938	2,575	2,557	2,529	2,144	2,080	2,053	1,753	—
	18,527	17,768	16,586	15,418	13,155	10,758	9,478	10,271	8,922	8,090
	16,738	16,426	14,430	11,582	9,580	9,048	7,106	5,270	5,025	4,429
	-693.57	-1,307	-677.85	-494.32	-171.45	-4,567	-4,306	-260.64	-1,214	-950.50
	16,045	15,119	13,752	11,088	9,408	4,481	2,799	5,010	3,810	3,479
	3,872	3,554	2,772	1,439	847.59	1,076	514.69	822.80	600.88	845.19
	12,117	11,509	10,965	9,610	8,513	3,389	2,272	4,172	3,208	2,608
	50.40	47.80	45.60	39.90	35.30	13.60	12.10	15.69	11.11	—
Key metrics
	19,385	18,396	16,559	13,883	12,110	6,752	5,021	7,365	6,119	3,997
	32.36%	31.50%	31.50%	28.60%	27.60%	17.50%	15.00%	22.40%	21.10%	15.10%
	20.23%	19.70%	20.90%	19.80%	19.40%	8.80%	6.80%	12.70%	11.00%	9.80%
	—	17.90%	18.90%	—	—	—	—	—	—	—
	—	11.20%	8.40%	10.50%	13.50%	15.40%	2.00%	13.00%	9.70%	—
	—	5.00%	14.10%	12.90%	151.20%	49.20%	-45.50%	30.10%	23.00%	—
	—	8,810	11,944	—	—	—	—	—	—	—
	—	1.08	1.28	—	—	—	—	—	—	—
	—	0.05	0.03	—	—	—	—	—	—	—
	—	-5,689	-8,399	—	—	—	—	—	—	—
	—	122.8	118.8	—	—	—	—	—	—	—
Balance sheet
	—	1,08,785	92,101	—	—	—	—	—	—	—
	—	63,860	52,594	—	—	—	—	—	—	—
	—	9,771	10,269	—	—	—	—	—	—	—
	—	15,510	13,046	—	—	—	—	—	—	—
	—	11,493	10,243	—	—	—	—	—	—	—
	—	2,865	2,528	—	—	—	—	—	—	—
	—	11,114	10,036	—	—	—	—	—	—	—
	—	7,334	6,184	—	—	—	—	—	—	—
	—	22,622	18,194	—	—	—	—	—	—	—
	—	4,082	1,870	—	—	—	—	—	—	—
	—	4,050	1,867	—	—	—	—	—	—	—
	—	31.26	2.52	—	—	—	—	—	—	—
	—	83,880	72,486	—	—	—	—	—	—	—
Cash flow
	—	12,419	14,072	—	—	—	—	—	—	—
	—	-11,344	-5,306	—	—	—	—	—	—	—
	—	-2,513	-7,906	—	—	—	—	—	—	—
	—	3,609	2,129	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	5,741	4,924	5,688	4,548	5,602	7,186	6,192	5,128	4,498	5,639	5,074	5,096
	140.17	62.93	179.90	72.79	103.69	132.00	68.39	86.30	82.74	118.88	76.80	106.54
	4,363	4,138	4,512	3,949	4,233	4,706	4,995	4,318	4,323	4,356	4,329	4,296
	1,240	1,229	1,160	996.19	1,067	1,330	1,163	1,225	973.23	1,056	1,122	1,067
	275.04	311.91	413.27	338.09	328.25	325.70	367.48	360.09	306.26	289.50	227.20	264.65
	830.93	703.99	739.62	728.77	715.00	648.91	651.68	662.19	645.48	575.97	590.13	600.41
	278.48	216.92	244.17	248.33	223.29	217.42	215.96	243.75	216.08	217.59	214.92	193.63
	307.92	325.97	338.53	336.30	299.03	291.96	290.97	285.53	369.81	393.04	399.60	392.71
	1,450	1,696	1,685	1,286	1,504	1,894	2,101	1,813	1,836	1,785	1,798	1,735
	1,518	849.01	1,356	671.75	1,473	2,612	1,265	895.64	257.92	1,402	821.28	906.52
	-31.53	0.00	-258.70	0.00	-287.64	0.00	—	—	—	—	-69.81	—
	1,486	849.01	1,097	671.75	1,185	2,612	1,265	895.64	257.92	1,402	751.47	906.52
	371.31	240.31	391.66	107.53	431.35	611.62	83.88	32.35	20.10	534.18	30.16	17.89
	1,115	608.70	705.44	564.22	753.53	2,000	1,181	863.29	237.82	867.60	721.31	888.63
	4.60	2.50	2.90	2.40	3.10	8.30	4.90	3.60	1.00	3.60	3.00	3.70
Key metrics
	2,073	1,392	1,680	1,256	1,707	3,121	1,772	1,425	843.81	2,012	1,366	1,493
	36.10%	28.30%	29.50%	27.60%	30.50%	43.40%	28.60%	27.80%	18.80%	35.70%	26.90%	29.30%
	19.40%	12.40%	12.40%	12.40%	13.50%	27.80%	19.10%	16.80%	5.30%	15.40%	14.20%	17.40%
	—	2.90%	—	3.60%	—	11.30%	—	—	—	—	—	—
	2.50%	-31.50%	-8.10%	-11.30%	24.50%	27.40%	22.00%	0.60%	—	—	—	—
	48.00%	-69.60%	-40.30%	-34.60%	216.80%	130.60%	63.70%	-2.90%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	20,901	20,755	23,003	20,275	20,812	15,586	12,803	12,532	10,303	7,948
	455.79	419.33	369.43	465.76	279.03	957.92	150.22	1,511	1,271	1,128
	16,962	16,834	18,342	17,072	16,412	14,417	10,711	10,790	9,641	8,645
	4,625	4,383	4,691	4,429	5,166	4,585	3,809	3,202	2,728	2,168
	1,338	1,392	1,360	994.41	1,126	1,249	1,200	1,227	1,197	1,166
	3,003	2,911	2,608	2,374	2,157	2,001	1,798	1,703	1,571	1,618
	987.90	947.84	893.21	784.08	472.18	388.10	256.98	408.01	540.92	388.31
	1,309	1,312	1,238	1,601	1,601	1,350	586.81	561.56	552.95	432.23
	6,117	6,194	7,621	6,797	6,178	5,266	3,260	3,514	3,302	2,714
	4,395	4,340	5,031	3,669	4,679	2,127	2,242	3,253	1,934	430.52
	-290.23	-546.34	0.00	-219.02	-2,938	-1,821	-89.56	—	-1,214	-950.50
	4,104	3,794	5,031	3,450	1,741	306.86	2,153	3,253	719.45	-519.98
	1,111	1,171	747.95	591.47	50.33	406.85	13.17	41.86	97.15	25.39
	2,994	2,623	4,283	2,858	1,691	-99.99	2,140	3,211	816.60	-494.59
	12.40	10.90	17.80	11.90	7.00	-0.40	8.92	13.38	3.40	—
Key metrics
	6,401	6,054	7,162	5,834	3,814	2,045	2,997	4,223	1,813	300.56
	30.63%	29.20%	31.10%	28.80%	18.30%	13.10%	23.40%	33.70%	17.60%	3.80%
	14.32%	12.60%	18.60%	14.10%	8.10%	-0.60%	16.70%	25.60%	7.90%	-6.20%
	—	13.00%	23.60%	—	—	—	—	—	—	—
	—	-9.80%	13.50%	-2.60%	33.50%	21.70%	2.20%	21.60%	29.60%	—
	—	-38.70%	49.80%	69.10%	1,790.90%	-104.70%	-33.40%	293.20%	265.10%	—
	—	4,958	3,488	—	—	—	—	—	—	—
	—	2.48	0.98	—	—	—	—	—	—	—
	—	0.60	0.45	—	—	—	—	—	—	—
	—	13,002	10,462	—	—	—	—	—	—	—
	—	192.4	191.3	—	—	—	—	—	—	—
Balance sheet
	—	43,060	43,273	—	—	—	—	—	—	—
	—	16,679	18,722	—	—	—	—	—	—	—
	—	417.84	492.02	—	—	—	—	—	—	—
	—	10,166	11,701	—	—	—	—	—	—	—
	—	4,302	3,787	—	—	—	—	—	—	—
	—	1,447	1,044	—	—	—	—	—	—	—
	—	5,145	4,345	—	—	—	—	—	—	—
	—	3,533	3,434	—	—	—	—	—	—	—
	—	6,503	18,149	—	—	—	—	—	—	—
	—	13,420	10,954	—	—	—	—	—	—	—
	—	0.00	10,954	—	—	—	—	—	—	—
	—	13,420	0.00	—	—	—	—	—	—	—
	—	22,371	24,340	—	—	—	—	—	—	—
Cash flow
	—	6,501	4,199	—	—	—	—	—	—	—
	—	-1,381	-209.56	—	—	—	—	—	—	—
	—	-5,230	-3,831	—	—	—	—	—	—	—
	—	1,543	710.51	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: -0.09%
Sales CAGR 5Y: +10.14%
Sales CAGR 10Y: —
Profit CAGR 3Y: +15.77%
Profit CAGR 5Y: +4.16%
Profit CAGR 10Y: —
Sales YoY (TTM): -13.30%
Profit YoY (TTM): -37.61%

Consolidated

Sales CAGR 3Y: +10.03%
Sales CAGR 5Y: +11.78%
Sales CAGR 10Y: —
Profit CAGR 3Y: +10.57%
Profit CAGR 5Y: +38.33%
Profit CAGR 10Y: —
Sales YoY (TTM): +11.41%
Profit YoY (TTM): +16.54%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 54.46%

Holder	Type	Holding	Previous	Change
Shanghvi Finance Private Limited	Promoter Group	40.30%	—	—
Dilip.S.Shanghvi	Promoter	9.60%	—	—
Life Insurance Corporation Of India	Public	5.53%	—	—
Icici Prudential Value Fund	Public	3.72%	—	—
Sbi Nifty 50 Etf	Public	2.36%	—	—
Nps Trust- A/C Hdfc Pension Fund Management Limited Scheme E - Tier I	Public	1.88%	—	—
Aditya Medisales Limited	Promoter Group	1.67%	—	—
Nippon Life India Trustee Ltd-A/C Nippon India Large Cap Fund	Public	1.38%	—	—
Raksha Sudhir Valia	Promoter Group	1.20%	—	—
Government Pension Fund Global	Public	1.03%	—	—
Lakshdeep Investments & Finance (P) Ltd.	Public	1.02%	—	—
Sudhir Vrundavandas Valia	Promoter Group	0.60%	—	—
Unimed Investments Limited	Promoter Group	0.43%	—	—
Vibha Dilip Shanghvi	Promoter Group	0.37%	—	—
Aalok Dilip Shanghvi	Promoter Group	0.12%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

As attached11 Sep 2026 · Company Update / General
Incorporation of wholly owned subsidiary of the Company in the International Financial Services Centre at GIFT City, Gandhinagar, Gujarat, India9 Sep 2026 · Company Update / General
International Credit Ratings8 Sep 2026 · Company Update / Credit Rating
Intimation of Schedule of Analyst/Institutional Investor Meeting3 Sep 2026 · Company Update / Analyst / Investor Meet
Sun Pharma participates in White House Signing Ceremony highlighting U.S. Medicines Pricing and Access Commitments1 Sep 2026 · Company Update / Press Release / Media Release
Newspaper Advertisements about Postal Ballot/E-voting26 Aug 2026 · Company Update / Newspaper Publication
Notice of Postal Ballot/E-voting25 Aug 2026 · AGM/EGM / Postal Ballot
Intimation of Schedule of Analyst/Institutional Investor Meeting25 Aug 2026 · Company Update / Analyst / Investor Meet
Update on Lipitor Antitrust Litigation17 Aug 2026 · Company Update / General
Receipt of No-objection letters from the Stock Exchanges for Reclassification of Promoter Group6 Aug 2026 · Company Update / General
Q1FY27 Earnings Call Transcript6 Aug 2026 · Company Update / Earnings Call Transcript
Intimation of Schedule of Analyst/Institutional Investor Meeting5 Aug 2026 · Company Update / Analyst / Investor Meet
Update on Credit Rating5 Aug 2026 · Company Update / Credit Rating
Newspaper Advertisement1 Aug 2026 · Company Update / Newspaper Publication
Voting Results for 34th AGM31 Jul 2026 · Company Update / General
Outcome of the 34th Annual General Meeting held on 31 July 202631 Jul 2026 · AGM/EGM / AGM
SPIL Q1FY27-Investor Call Audio Recording31 Jul 2026 · Company Update / General
Conclusion of the Board Meeting held today31 Jul 2026 · Company Update / General
Quarterly Financial Results for Q1 of FY 2026-2731 Jul 2026 · Result / Financial Results
Sun Pharma receives approval to manufacture and market semaglutide in Brazil29 Jul 2026 · Company Update / Press Release / Media Release
Newspaper advertisement about opening of Special Window, for transfer of physical shares28 Jul 2026 · Company Update / Newspaper Publication
Update on Nidlegy27 Jul 2026 · Company Update / General
Sun Pharma notes Organon Shareholder approval for proposed acquisition24 Jul 2026 · Company Update / Press Release / Media Release
Press Release15 Jul 2026 · Company Update / Press Release / Media Release
Sun Pharma to announce first quarter results on 31 July 2026 Earnings call scheduled on Friday, 06.30 pm IST, 31 July 202614 Jul 2026 · Company Update / Analyst / Investor Meet
Sun Pharmaceutical Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve Unaudited Standalone ....10 Jul 2026 · Board Meeting / Board Meeting
Investor Presentation -June 20267 Jul 2026 · Company Update / Investor Presentation
Newspaper Publication7 Jul 2026 · Company Update / Newspaper Publication
Submission of Confirmation Certificate for the quarter ended 30 June 2026.6 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Notice of 34th Annual General Meeting along with the Annual Report for FY 2025-266 Jul 2026 · AGM/EGM / AGM
Annual Report 2025-26 and the Notice of 34th Annual General Meeting6 Jul 2026 · Others / Reg. 34 (1) Annual Report
Newspaper Advertisement26 Jun 2026 · Company Update / Newspaper Publication
Closure of trading window25 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Acquisition of Innovcare Lifesciences Private Limited20 Jun 2026 · Company Update / Acquisition
Information about transfer of equity shares and unclaimed dividends to the Investor Education and Protection Fund (IEPF) Account16 Jun 2026 · Company Update / Newspaper Publication
As attached14 Jun 2026 · Company Update / General
Intimation of Record Date12 Jun 2026 · Corp. Action / Record Date
Intimation of Record Date for Final Dividend11 Jun 2026 · Corp. Action / Dividend
Intimation of 34th AGM and Record Date for Final Dividend11 Jun 2026 · Company Update / General
Transcript for 22 May 2026 Analyst Meet29 May 2026 · Company Update / Earnings Call Transcript

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 5.0000	7 Jul 2026	7 Jul 2026	—
Interim Dividend - Rs. - 11.0000	5 Feb 2026	5 Feb 2026	—
Final Dividend - Rs. - 5.5000	7 Jul 2025	7 Jul 2025	—
Interim Dividend - Rs. - 10.5000	6 Feb 2025	6 Feb 2025	—
Final Dividend - Rs. - 5.0000	12 Jul 2024	12 Jul 2024	—

Board meetings

31 Jul 2026 Board Meeting - Financial Results